Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALIZE-K trial of sodium zirconium cyclosilicate for hyperkalemia management in symptomatic heart failure with reduced ejection fraction receiving spironolactone
2020-003312-27Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hyperkalemia comparing SZC with Placebo (2 arms). Started Dec 2020; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2020-003312-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003312-27.